Figure 4: Time to First Occurrence of Hospitalization for Heart Failure or CV Death in the DECLARE Trial Figure 5: Time to First Occurrence of Hospitalization for Heart Failure in the DECLARE Trial 14.4 Chronic Kidney Disease The Trial to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients with Chronic Kidney Disease (DAPA-CKD, NCT03036150) was an international, multicenter, randomized, double-blind, placebo-controlled trial in adult patients with chronic kidney disease (CKD) (eGFR between 25 and 75 mL/min/1.73 m2) and albuminuria [urine albumin creatinine ratio (UACR) between 200 and 5000 mg/g] who were receiving standard of care background therapy, including a maximally tolerated, labeled daily dosage of an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB)
PMID 23668655
Potential Benefits & Side Effects Observations from preclinical and clinical literature on IGF-1 and its analogs
Business Type Exporter, Importer, Manufacturer, Distributor, Supplier, Trading Company, Wholesaler, Retailer Employee Count 10 Establishment 2015 Working Days To GST NO 27ADFPA9422N1ZD Related Products Explore Related Categories More Products From This Seller Seller Details GST - 27ADFPA9422N1ZD Mumbai, Maharashtra Marketing Manager Mr Ramesh Address Plot No
Keep your eye out for the following: Breeds most prone to cataract problems are:
Search our store
